Loading...
•
Dec 31, 2021
Evolent Health Q4 2021 Earnings Report
Evolent Health's Q4 2021 financial results were announced, revealing a slight increase in GAAP revenue and a net loss attributable to common shareholders.
Key Takeaways
Evolent Health reported GAAP revenue of $248.4 million for Q4 2021, a 0.7% increase year-over-year. The company experienced a net loss of $(5.6) million attributable to common shareholders. Adjusted EBITDA reached $24.3 million.
GAAP revenue increased by 0.7% to $248.4 million.
Revenue excluding divested assets increased by 39.7%.
Net loss attributable to common shareholders was $(5.6) million.
Adjusted EBITDA was $24.3 million.
Evolent Health
Evolent Health
Forward Guidance
For Q1 2022, Evolent Health projects revenue between $280.0 million and $295.0 million, with adjusted EBITDA between $20.0 million and $25.0 million. For FY 2022, revenue is expected to range from $1.12 billion to $1.18 billion, and adjusted EBITDA is projected between $80.0 million and $90.0 million.
Positive Outlook
- Revenue for Q1 2022 is expected to be in the range of approximately $280.0 million to $295.0 million.
- Adjusted EBITDA for Q1 2022 is expected to be in the range of approximately $20.0 million to $25.0 million.
- Revenue for the year ending December 31, 2022 is expected to be in the range of approximately $1.12 billion to $1.18 billion.
- Adjusted EBITDA for the year ending December 31, 2022 is expected to be in the range of approximately $80.0 million to $90.0 million.
- Cash deployed for software development is expected to be in the range of $25 million - $30 million.